Brief: Yichang Hec Changjiang Pharmaceutical Says Insulin Aspart 30 Injection Obtained Approval For Launch From China NMPA
Nov 8 (Reuters) - YiChang HEC ChangJiang Pharmaceutical
Co Ltd 1558.HK :
* INSULIN ASPART 30 INJECTION OBTAINED APPROVAL FOR LAUNCH
FROM
CHINA NMPA
Further company coverage: 1558.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Yichang Hec Changjiang Pharmaceutical Co
See all newsBrief: Yichang Hec Changjiang Pharmaceutical Says Exchange Approved Withdrawal Of Listing Of H Shares
Brief: Yichang Hec Changjiang Pharmaceutical Says Encofosbuvir Tablets (0.3G) Approved For Launch By NMPA
Brief: Yichang HEC Changjiang Pharmaceutical Updates On Filing With Listing Committee
Brief: YiChang HEC Changjiang Pharmaceutical Says Sunshine Lake Pharma To Enter Licensing Agreement
Brief: YiChang HEC Changjiang Pharmaceutical Posts HY Revenue RMB2,454.8 Million